Redeye maintains its positive view of Heliospectra on the back of the Q1-report. Heliospectra reported sales of SEK 15m and EBIT of SEK -8m in the first quarter, in line with our estimate of 17m in sales and -8m EBIT. Our current valuation prices in effects from the Coronacrisis with a tough Q2 and we do not see strong reasons to rush into the share at this point, as we believe both deliveries of the large order book and new potential agreements are likely to be offset.